Zepbound 7.5mg Mid-Dose Availability October 2026
In medical practice, the ongoing GLP-1 shortage poses significant patient care difficulties that extend past mere inconvenience. Here’s what you should know.
Medical Consequences
Treatment gaps from shortages produce quantifiable health consequences:
Metabolic Effects
When patients abruptly stop semaglutide or tirzepatide:
- Rapid weight regain: Studies show approximately two-thirds of weight loss comes back within 6–12 months of discontinuation
- Glycemic control loss: For diabetic patients, blood sugar management increases within weeks
- Appetite return: Appetite suppression ceases soon after drug washout
- Emotional consequences: Anxiety, loss of control, and disordered eating patterns are documented
Medical Approaches
Dose Modification
Should the target dose can’t be sourced:
- Dose reduction: Switching to whatever strength is in stock maintains some therapeutic benefit and reduces the risk of total discontinuation
- Longer injection gaps: Taking the available dose every 10–14 days instead of the standard interval — not ideal but preferable to stopping
- Dose splitting: If the delivery device permits, splitting a higher dose into smaller administrations
Drug Switching
When a specific medication can’t be found anywhere:
- Cross-class substitution: Needs thoughtful cross-titration — the pharmacology differs
- Changing delivery method: Pen to tablet is possible but absorption is different
- Alternative drug classes: Other pharmacotherapy as a bridge while waiting for supply
Patient Communication
Healthcare professionals should:
- Communicate honestly about how long this may last — patients deserve better outcomes than false hope
- Keep detailed records — all clinical adaptations need recording
- Give patients a plan for what to do if their pharmacy is disrupted
- Monitor more closely during treatment adjustments — patients on suboptimal doses require closer monitoring
Systemic Issues
Drug shortages aren’t new — but the GLP-1 shortage is unique in scale and impact.
Structural changes need:
- Expanded manufacturing — already underway but still ramping up
- Smarter supply chains — ensuring equitable access
- Regulatory flexibility — like shortage designations that keep pace with market realities
Until then, everyone need to work through these difficult conditions together.